A Comparison of Intramuscular and Subcutaneous Administration of LigA Subunit Vaccine Adjuvanted with Neutral Liposomal Formulation Containing Monophosphoryl Lipid A and QS21

Leptospirosis vaccines with higher potency and reduced adverse effects are needed for human use. The carboxyl terminal domain of leptospiral immunoglobulin like protein A (LigAc) is currently the most promising candidate antigen for leptospirosis subunit vaccine. However, LigAc-based vaccines were u...

Descripción completa

Detalles Bibliográficos
Autores principales: Techawiwattanaboon, Teerasit, Barnier-Quer, Christophe, Palaga, Tanapat, Jacquet, Alain, Collin, Nicolas, Sangjun, Noppadon, Komanee, Pat, Patarakul, Kanitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565420/
https://www.ncbi.nlm.nih.gov/pubmed/32882903
http://dx.doi.org/10.3390/vaccines8030494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565420/
https://www.ncbi.nlm.nih.gov/pubmed/32882903
http://dx.doi.org/10.3390/vaccines8030494

Ejemplares similares